AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Cynata will present two-year patient follow-up data from its Phase 1 clinical trial of CYP-001 in SR-aGvHD at a prestigious stem cell conference, ISCT.
- ISCT, a major international conference, will be attended by delegates from more than 50 countries.
- The presentation at the conference will highlight the two-year overall survival rate in patients treated with CYP-001 comparing highly favourably to previously published outcomes.
- Also, there were no serious adverse events or safety concerns.
Cynata Therapeutics Limited (ASX: CYP) has announced a positive update concerning CYP-001, the company’s Cymerus™ mesenchymal stem cell (MSC) product candidate for acute graft versus host disease (aGvHD).
The clinical-stage biotechnology company will present the encouraging data on CYP-001 from the trial in patients with steroid-resistant (SR) aGvHD at the upcoming Annual Meeting of the International Society for Cell and Gene Therapy (ISCT) in Paris, France.
The ISCT oral presentation will be delivered by Professor John Rasko, AO, (Head of Department, Cell & Molecular Therapies, Royal Prince Alfred Hospital, Sydney; Professor, Faculty of Medicine & Health, The University of Sydney; and Head, Gene and Stem Cell Therapy Program, Centenary Institute, Sydney) and will include two-year patient follow-up data from the Phase 1 clinical trial of CYP-001 in 15 patients with SR-aGvHD . The long-term data follows highly promising results from the primary evaluation at Day 100 with Complete Response and Overall Response rates marked at 53% and 87%, respectively.
The two-year follow-up demonstrates a sustained result with overall survival at 60% (9/15 patients), without any treatment-related serious adverse events or safety concerns detected. This survival rate compares very favourably to previously reported outcomes in SR-aGvHD, where longer term survival is typically less than 40%, says the company.
